| Prospectus addendum To the prospectus dated April 13, 2023 and the prospectus supplement dated April 13, 2023 |
Registration Statement Nos. 333-270004 and 333-270004-01 Dated April 13, 2023 Rule 424(b)(3) |
| JPMorgan Chase & Co. |
JPMorgan Chase Financial Company LLC
|
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have filed a prospectus dated April 13, 2023 (the “Prospectus”) and a prospectus supplement dated April 13, 2023 (the “Prospectus Supplement”) with the Securities and Exchange Commission. With respect to each preliminary pricing supplement dated prior to the date of this prospectus addendum relating to an offering with a pricing date on or after the date of this prospectus addendum (each, a “Preliminary Pricing Supplement”):
| · | all references to the prospectus of JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC dated April 8, 2020 (the “Original Prospectus”) (or to any section of the Original Prospectus) are deemed to refer instead to the Prospectus (or to the corresponding section of the Prospectus); and |
| · | all references to the prospectus supplement of JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC dated April 8, 2020 (the “Original Prospectus Supplement”) (or to any section of the Original Prospectus Supplement) are deemed to refer instead to the Prospectus Supplement (or to the corresponding section of the Prospectus Supplement). |
JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have also filed the product supplements set forth under the heading “Replacement Product Supplement” in the table below (each, a “Replacement Product Supplement”) with the Securities and Exchange Commission. With respect to each Preliminary Pricing Supplement, all references to any product supplement set forth under the heading “Original Product Supplement” in the table below (each, a “Original Product Supplement”) (or to any section of that Original Product Supplement) are deemed to refer instead to the relevant Replacement Product Supplement (or to the corresponding section of that Replacement Product Supplement) as set forth in the table below.
| Original Product Supplement | Replacement Product Supplement |
| Product supplement no. 1-II dated November 4, 2020 | Product supplement no. 1-I dated April 13, 2023 |
| Product supplement no. 2-II dated November 4, 2020 | Product supplement no. 2-I dated April 13, 2023 |
| Product supplement no. 3-II dated November 4, 2020 | Product supplement no. 3-I dated April 13, 2023 |
| Product supplement no. 4-II dated November 4, 2020 | Product supplement no. 4-I dated April 13, 2023 |
| Product supplement no. 5-II dated November 4, 2020 | Product supplement no. 5-I dated April 13, 2023 |
| Product supplement no. 6-I dated April 8, 2020 | Product supplement no. 6-I dated April 13, 2023 |
| Product supplement no. MS-1-II dated November 4, 2020 | Product supplement no. 4-I dated April 13, 2023 |
| Product supplement no. UBS-1-II dated November 4, 2020 | Product supplement no. UBS-1-I dated April 13, 2023 |
| Product supplement no. WF-1-I dated March 18, 2022 | Product supplement no. WF-1-I dated April 13, 2023 |
In addition, JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have filed the underlying supplements set forth under the heading “Replacement Underlying Supplement” in the table below (each, a “Replacement Underlying Supplement”) with the Securities and Exchange Commission. With respect to each Preliminary Pricing Supplement, all references to any underlying supplement set forth under the heading “Original Underlying Supplement” in the table below (the “Original Underlying Supplement”) (or to any section of that Original Underlying Supplement) are deemed to refer instead to the relevant Replacement Underlying Supplement (or to the corresponding section of that Replacement Underlying Supplement) as set forth in the table below.
| Original Underlying Supplement | Replacement Underlying Supplement |
| Underlying supplement no. 1-II dated November 4, 2020 | Underlying supplement no. 1-I dated April 13, 2023 |
| Underlying supplement no. 5-I dated October 13, 2022 | Underlying supplement no. 5-I dated April 13, 2023 |
| Underlying supplement no. 6-III dated August 31, 2021 | Underlying supplement no. 6-I dated April 13, 2023 |
| Underlying supplement no. 8-II dated August 31, 2021 | Underlying supplement no. 8-I dated April 13, 2023 |
| Underlying supplement no. 9-II dated August 31, 2021 | Underlying supplement no. 9-I dated April 13, 2023 |
| Underlying supplement no. 11-I dated October 19, 2021 | Underlying supplement no. 11-I dated April 13, 2023 |
| Underlying supplement no. 13-I dated February 1, 2022 | Underlying supplement no. 13-I dated April 13, 2023 |
| Original Underlying Supplement | Replacement Underlying Supplement |
| Underlying supplement no. 14-I dated February 22, 2022 | Underlying supplement no. 14-I dated April 13, 2023 |
| Underlying supplement no. 17-II dated October 12, 2022 | Underlying supplement no. 17-I dated April 13, 2023 |
| Underlying supplement no. 18-II dated October 12, 2022 | Underlying supplement no. 18-I dated April 13, 2023 |
| Underlying supplement no. 19-I dated March 31, 2023 | Underlying supplement no. 19-I dated April 13, 2023 |
| Underlying supplement no. 21-I dated April 3, 2023 | Underlying supplement no. 21-I dated April 13, 2023 |
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this prospectus addendum or any Relevant Supplement, the Prospectus Supplement or the Prospectus. Any representation to the contrary is a criminal offense.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.
April 13, 2023